MSC Senescence-Related Genes Are Associated with Myeloma Prognosis and Lipid Metabolism-Mediated Resistance to Proteasome Inhibitors

Figure 7

Differential bortezomib resistance and differential gene enrichment in the high and low-risk groups of GSE4581. (a) A boxplot of differences in predicted bortezomib IC50 between the high-risk and low-risk groups. (b) Enrichment pathways of genes upregulated in myeloma in the high-risk group than in the low-risk group. (c) Enrichment pathways of genes downregulated by myeloma in the high-risk group than in the low-risk group.

(a)

(b)

(c)